MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-04-2026
Hutchison China MediTech Limited Cash and Cash Equivalents 2011-2026 | HCM
Annual Cash and Cash Equivalents Hutchison China MediTech Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 236 M | 121 M | 86 M | 85.3 M | 79.4 M | 31.9 M | 38.9 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 236 M | 31.9 M | 96.9 M |
Quarterly Cash and Cash Equivalents Hutchison China MediTech Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 378 M | - | 587 M | - | 236 M | - | 49.9 M | - | 121 M | 97.1 M | 83.4 M | 91.7 M | 86 M | 116 M | 75.3 M | 78.1 M | 85.3 M | - | 113 M | - | 79.4 M | - | 76 M | - | 31.9 M | - | - | - | 38.9 M | - | - | - | 46.9 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 587 M | 31.9 M | 130 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B |  France |
 |
Autolus Therapeutics plc
AUTL
|
104 M | $ 1.36 | -2.52 % | $ 362 M |  Britain |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K |  USA |
 |
DBV Technologies S.A.
DBVT
|
194 M | $ 20.25 | -0.54 % | $ 2.83 B | France |
 |
Dyadic International
DYAI
|
4.62 M | $ 0.87 | 0.59 % | $ 31.5 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
34.8 M | $ 3.78 | 4.83 % | $ 9.09 B |  Australia |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | USA |
 |
Aytu BioScience
AYTU
|
31 M | $ 2.6 | -2.26 % | $ 16.3 M | USA |
 |
Fate Therapeutics
FATE
|
46.6 M | $ 1.14 | -4.2 % | $ 135 M | USA |
 |
Forte Biosciences
FBRX
|
77 M | $ 26.44 | - | $ 342 M | USA |
 |
Aeterna Zentaris
AEZS
|
16.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
Fennec Pharmaceuticals
FENC
|
36.8 M | $ 6.16 | -4.05 % | $ 176 M | USA |
 |
AgeX Therapeutics
AGE
|
3.06 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
Amicus Therapeutics
FOLD
|
214 M | $ 14.46 | 0.03 % | $ 4.46 B | USA |
 |
AIkido Pharma
AIKI
|
34 M | - | 1.93 % | $ 17.4 M | USA |
 |
Fulcrum Therapeutics
FULC
|
198 M | $ 7.57 | -3.32 % | $ 480 K | USA |
 |
Aptose Biosciences
APTO
|
935 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Galectin Therapeutics
GALT
|
17.7 M | $ 2.28 | -11.13 % | $ 146 M | USA |
 |
Gilead Sciences
GILD
|
7.56 B | $ 138.34 | -1.28 % | $ 172 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
6.95 M | $ 0.54 | 4.28 % | $ 503 K |  Israel |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
Genmab A/S
GMAB
|
3.55 B | $ 27.14 | -2.2 % | $ 17 B |  Danmark |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
BioNTech SE
BNTX
|
7.68 B | $ 88.2 | -3.37 % | $ 27.2 B | Germany |
 |
Gossamer Bio
GOSS
|
37.7 M | $ 0.32 | -7.11 % | $ 73.1 M | USA |
 |
Coherus BioSciences
CHRS
|
88.9 M | $ 1.62 | -3.29 % | $ 190 M | USA |
 |
Grifols, S.A.
GRFS
|
980 M | $ 7.98 | -3.04 % | $ 6.83 B |  Spain |
 |
Akari Therapeutics, Plc
AKTX
|
2.6 M | $ 3.5 | -1.13 % | $ 236 B | Britain |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
GT Biopharma
GTBP
|
6.81 M | $ 0.41 | -8.56 % | $ 2.26 M | USA |
 |
Allakos
ALLK
|
66.4 M | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
30 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
1.66 B | $ 316.69 | -4.13 % | $ 41.5 B | USA |
 |
Halozyme Therapeutics
HALO
|
134 M | $ 63.72 | 1.01 % | $ 7.64 B | USA |
 |
Alpine Immune Sciences
ALPN
|
13.4 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
3.22 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
98.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Harmony Biosciences Holdings
HRMY
|
753 M | $ 27.53 | -0.67 % | $ 1.58 B | USA |
 |
Burford Capital Limited
BUR
|
322 M | $ 4.53 | 1.0 % | $ 726 M | Britain |
 |
Atreca
BCEL
|
30.8 M | - | -11.76 % | $ 5.79 M | USA |